Biotech company Trogenix has secured £70 million ($95 million) in funding to help advance its pipeline of cancer therapies.   The Series A funding was led by IQ Capital and invested in by 4BIO Capital, alongside new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. The round also included returning investors, the National Brain […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!